Voyager Therapeutics Inc (VYGR) Expected to Post Quarterly Sales of $2.90 Million

Brokerages expect that Voyager Therapeutics Inc (NASDAQ:VYGR) will announce $2.90 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Voyager Therapeutics’ earnings. The highest sales estimate is $5.00 million and the lowest is $2.00 million. Voyager Therapeutics posted sales of $6.35 million in the same quarter last year, which would indicate a negative year over year growth rate of 54.3%. The firm is scheduled to report its next earnings report on Wednesday, March 13th.

According to Zacks, analysts expect that Voyager Therapeutics will report full year sales of $8.86 million for the current financial year, with estimates ranging from $7.61 million to $11.15 million. For the next fiscal year, analysts anticipate that the firm will post sales of $23.08 million, with estimates ranging from $8.00 million to $68.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Voyager Therapeutics.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Wednesday, November 7th. The company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.15. Voyager Therapeutics had a negative net margin of 648.40% and a negative return on equity of 81.63%. The business had revenue of $2.09 million for the quarter, compared to the consensus estimate of $3.02 million.

VYGR has been the topic of several recent research reports. HC Wainwright set a $25.00 price target on shares of Voyager Therapeutics and gave the stock a “buy” rating in a research report on Friday, November 9th. ValuEngine upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, November 6th. BTIG Research reiterated a “buy” rating and issued a $32.00 price target on shares of Voyager Therapeutics in a research report on Monday, September 10th. Zacks Investment Research upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Saturday, November 17th. Finally, Morgan Stanley downgraded shares of Voyager Therapeutics from an “overweight” rating to an “equal” rating in a research report on Monday, September 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. Voyager Therapeutics has an average rating of “Buy” and a consensus target price of $26.56.

VYGR opened at $9.62 on Friday. Voyager Therapeutics has a 1-year low of $8.30 and a 1-year high of $31.91. The company has a market capitalization of $308.31 million, a price-to-earnings ratio of -3.64 and a beta of 2.73.

Hedge funds have recently made changes to their positions in the company. BB Biotech AG increased its holdings in Voyager Therapeutics by 11.5% in the 3rd quarter. BB Biotech AG now owns 2,822,641 shares of the company’s stock valued at $53,404,000 after acquiring an additional 290,000 shares during the last quarter. BlackRock Inc. increased its holdings in Voyager Therapeutics by 1.0% in the 3rd quarter. BlackRock Inc. now owns 1,863,766 shares of the company’s stock valued at $35,262,000 after acquiring an additional 18,060 shares during the last quarter. Vanguard Group Inc. increased its holdings in Voyager Therapeutics by 10.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,196,594 shares of the company’s stock valued at $22,640,000 after acquiring an additional 113,442 shares during the last quarter. Vanguard Group Inc increased its holdings in Voyager Therapeutics by 10.5% in the 3rd quarter. Vanguard Group Inc now owns 1,196,594 shares of the company’s stock valued at $22,640,000 after acquiring an additional 113,442 shares during the last quarter. Finally, Wells Fargo & Company MN increased its holdings in Voyager Therapeutics by 18.6% in the 3rd quarter. Wells Fargo & Company MN now owns 534,087 shares of the company’s stock valued at $10,105,000 after acquiring an additional 83,607 shares during the last quarter. Hedge funds and other institutional investors own 88.57% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Read More: Cost of Capital Explained

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply